APOA1 and neoplasm: One strategy to unplug the cytotoxic activity of IFN-α from its immunostimulatory activity involves its fusion to apolipoprotein A-I.27 The apolipoprotein A-I moiety incorporates the cytokine into high-density lipoproteins, improving the pharmacokinetics and anti-tumour activity of IFN-α.28,29 AcTakines, activity-on-Target cytokines, can also minimise the toxicity of IFN-α and maximise its immunostimulatory activity.